A multimodal intervention for Alzheimer's disease results in multifaceted systemic effects reflected in blood and ameliorates functional and cognitive outcomes

Authors: Jared C. Roach[1], Lance Edens[1], Daria R. Markewych[1], Molly K. Rapozo[2], Junko Hara[3], Gustavo Glusman[1], Cory Funk[1], Jennifer Bramen[4], Priyanka Baloni[5], William R Shankle[3,6,7,8], Leroy Hood[1]

[1] Institute for Systems Biology, Seattle, WA, USA
[2] Providence St. Joseph Health, Renton, WA, USA
[3] Pickup Family Neurosciences Institute, Hoag Memorial Hospital Presbyterian, Newport Beach, CA, USA
[4] Pacific Neuroscience Institute Pacific Brain Health Center Santa Monica California USA
[5] Purdue University, IN, USA
[6] Department of Cognitive Sciences, University of California, Irvine, CA, USA
[7] Shankle Clinic, Newport Beach, CA, USA
[8] EMBIC Corporation, Newport Beach, CA, USA

Corresponding Author:
Jared C. Roach
401 Terry Ave N
Seattle WA 98109, United States
206-732-2108
jared.roach@isbscience.org

Funding: This work was supported by the Alzheimer's Translational Pillar of Providence St. Joseph Health, by the National Science Foundation (NSF) Research Experiences for Undergraduates site "Research Opportunities in Systems Biology", by the Saint John's Health Center Foundation, by the Pacific Neuroscience Institute Foundation (including the Cary and Will Singleton family), and by National Institutes of Health (NIH) grants R01AG062514, U01AG046139, RF1AG057443, & U01AG061359.

Keywords: diet, exercise, cognitive training, dementia, cognitive decline, Alzheimer's disease and related disorders (ADRD), Alzheimer's disease (AD), personalized coaching, remote coaching, COVID, systems biology, multimodal interventions, cognitive impairment, lifestyle, prospective randomized clinical trial (RCT)

Trial registration: ClinicalTrials.gov: NCT03424200 (clinicaltrials.gov/ct2/show/NCT03424200).

Abstract

Introduction. Comprehensive treatment of Alzheimer's disease and related dementias (ADRD) requires not only pharmacologic treatment but also management of existing medical conditions and lifestyle modifications including diet, cognitive training, and exercise. The Coaching for Cognition in Alzheimer's (COCOA) trial was a prospective randomized controlled trial (RCT) to test the hypothesis that a remotely coached multimodal lifestyle intervention would improve early-stage Alzheimer's disease (AD). AD results from the interplay of multiple interacting dysfunctional biological systems. Specific causes of AD differ between individuals. Personalized, multimodal therapies are needed to best prevent and treat AD. COCOA collected psychometric, clinical, lifestyle, genomic, proteomic, metabolomic and microbiome data at multiple timepoints across two years for each participant. These data enable systems-biology analyses. We report analyses of the first COCOA data freeze. This analysis includes an evaluation of the effect of the intervention on outcome measures. It also includes systems analyses to identify molecular mediators that convey the effect of personalized multimodal lifestyle interventions on amelioration of cognitive trajectory.

Methods. A total of 55 participants with early-stage AD from Southern California were randomized into two parallel arms. Arm 1 (control; N=24) received standard of care. Arm 2 (intervention; N=31) also received telephonic personalized coaching for multiple lifestyle interventions including diet, exercise, and cognitive training. COCOA's overarching aim was to gather dense molecular data from an AD cohort to improve understanding of pathophysiology and advance treatment. For the RCT, COCOA's objective was to test the hypothesis that the Memory Performance Index (MPI) trajectory would be better in the intervention arm than in the control arm. The Functional Assessment Staging Test (FAST) was assessed for a secondary outcome. Assessments were blinded. The nature of the intervention precluded participant blinding.

Results. The intervention arm ameliorated 2.6 ± 0.8 MPI points ($p = 0.0007$; $N = 48$) compared to the control arm over the two-year intervention. Top-ranked candidate mediators included: albumin, propionylcarnitine, sphingomyelin, hexadecanedioate, acetylkynurenine, tiglylcarnitine, IL18R1, palmitoyl-sphingosine-phosphoethanolamine, acetyltryptophan, and IL17D. These individual molecules implicated inflammatory and nitrogen/tryptophan metabolism pathways. No important adverse events or side effects were observed.

Conclusions. Clinical trials should include frequent assessment of dense data to maximize knowledge gained. Such knowledge is useful not only in testing a primary hypothesis, but also in advancing basic biological and pathophysiological knowledge, understanding mechanisms explaining trial results, generating synergistic knowledge tangential to preconceived hypotheses, and refining interventions for clinical translation. Data from every trial should allow an intervention to be refined and then tested in future trials, driving iterative improvement. Multimodal lifestyle interventions are effective for ameliorating cognitive decline and may have an effect size larger than pharmacological interventions. Effects may be molecularly idiosyncratic; personalization of interventions is important. Dietary changes and exercise are likely to be beneficial components of multimodal interventions in many individuals. Remote coaching is an effective intervention for early stage ADRD. Remote interventions were effective during the COVID pandemic.

1. Introduction

Complex diseases require complex therapies.[1] The COCOA trial was designed to test the hypothesis that multimodal interventions can slow progression, halt, or reverse — ameliorate — the course of Alzheimer's disease (AD). Intervention was delivered by telephonic coaching. This coaching leveraged knowledge from prior studies to choose interventions expected to ameliorate cognition, including diet, exercise, and cognitive training.

Our overall aim in COCOA is to explore four overarching hypotheses that (1) there are multiple causes of AD, (2) there are multiple interventions to ameliorate AD, (3) different individuals with AD will have different mixes of causes, and (4) the best treatment for any given individual should be personalized to include multimodal interventions that treat the specific causes of their AD (**Figure 1**). COCOA pre-specified a simple hypothesis to be tested — that the intervention group will have a better cognitive trajectory than the control group. However, proving this hypothesis (lemma #1) does little by itself to advance our four overarching hypotheses. In order to advance these hypotheses, we will also show that (lemma #2) the COCOA intervention causes broad multisystem changes reflected in numerous blood analytes, (lemma #3) several of these analytes are correlated with cognitive improvement and are thus candidate mediators of the effects of the multimodal interventions, (lemma #4) there are mediators & mechanisms shared by multiple individuals that suggest some shared mechanisms may be broadly applicable to many or most AD patients, (lemma #5) there may be some mediators operating in only one or a few COCOA participants, (lemma #6) that the mechanisms identified — both aggregate and individual — are not randomly distributed across all systems, and (lemma #7) that several identified mechanisms have considerable prior evidence for mediating AD interventions. Together these lemmas will bolster support for our four overarching hypotheses. They leverage the epistemological concepts of coherence — combining the ensemble of the data into *biological plausibility* (Fedak et al., 2015). This synergy is driven by the integration of knowledge from various evidence streams, particularly omics.

2. Methods

Methods for the COCOA trial were published as a separate manuscript (Roach, Hara, Fridman, et al., 2022). In brief, COCOA is a prospective randomized clinical trial (RCT) to test the hypothesis that coached multimodal interventions ameliorate cognitive decline. Main inclusion criteria: age 50 and older; Memory Performance Index (MPI; embic.us/application/clinical) of 65 or below. COCOA recruited, enrolled, and

---

[1] Abbreviations: AD, Alzheimer's disease; ADRD, Alzheimer's disease and related disorders (or nearly equivalently: Alzheimer's disease and related dementias), MCI, mild cognitive impairment; MCIS, MCI Screen; RCT, randomized controlled trial; MPI, Memory Performance Index; MoCA, Montreal Cognitive Assessment; FAST, Functional Assessment Staging Test.



Figure 1. The multimodal nature of Alzheimer's disease causes and treatments. Alzheimer's disease (AD) has multiple causes and treatments. Each individual may have a different subset of these causes and receive a different subset of these treatments. A number of bioentities may mediate the effects of these treatments, including molecular mediators (triangles). Some of these same bioentities may also have mediated the cause of the disease. Outcomes for each individual depend on appropriately matching treatments to their individual pathophysiology. In this manuscript we focus on identifying mediators for treatments that ameliorate AD. In some cases, the effects of mediators may be measured by non-causal analytes that serve as biomarkers for these mediators (pentagons). Every individual is unique, but shared mechanisms — in aggregate across a population — unify the concept of AD.

randomized 55 participants over 16 months, averaging over 3 enrollments per month (**Supplemental Figures 1 & 2**). The trial protocol as approved by the Western Institutional Review Board (WIRB; protocol #20172152) is included as **Appendix 1.** In April 2019, Arivale, our primary provider of trial logistics, ceased operations. Most operations previously contracted through Arivale were then assumed in house. Enrollment ceased due to Arivale ceasing operations. Circa March 2020, the COVID pandemic began. COVID increased risk for in-person activities. The intervention — telephonic coaching — was exceptionally robust (almost presciently so) to COVID disruptions. At least two blood draws were completed by 43 participants (**Supplemental Figure 3**). Baseline demographic characteristics are presented in **Table 1**.

3. Results and Intermediate Logical Steps (Lemmas)

We present our result in seven subsections, each corresponding to a lemma. Lemma #1 is our claim that the COCOA intervention results in cognitive and functional improvement. The other lemmas are: (lemma #2) the COCOA intervention causes broad multisystem changes reflected in numerous blood analytes, (lemma #3)



Figure 2. Aggregate MPI trajectory of COCOA Participants. The COCOA intervention ameliorates aggregate cognitive trajectory. Each MPI measurement from every participant is shown. Cognitive measurements vary considerably between individuals and over time. Change from baseline is graphed. The primary outcome measure is computed with linear regression and graphed in **Supplemental Figure 4**. However, as the aggregate cognitive trajectories of each arm are most likely non-linear, this figure (illustrated with spline trajectories) may more accurately convey the nature of the trajectories than a linear fit. The baseline is shown as a dark black line and serves as a reference for no change over time. The intervention arm diverges markedly from the control arm during the first several months of the trial, and then maintains a fairly constant improvement over the remaining months. Both trajectories eventually drop below baseline, but with the intervention arm losing relatively little cognition from baseline. Individual trajectories are graphed in **Supplemental Figure 5**. 90% confidence intervals are shaded.

several of these analytes are correlated with cognitive improvement and are thus candidate mediators of the effects of the multimodal interventions, (lemma #4) there are mediators & mechanisms shared by multiple individuals that suggest some shared mechanisms that may be broadly applicable to many or most AD patients, (lemma #5) there may be some mediators that may be operating in only one or a few COCOA participants, (lemma #6) identified mechanisms implicate specific subsystems, and (lemma #7) these mechanisms are already known to mediate AD interventions.

3.A. Lemma 1: The COCOA intervention causes an amelioration of cognitive and functional trajectories.

Cognition (MPI) is significantly ameliorated in the intervention arm. Linear regression showed an effect size of a 2.6 ± 0.8 MPI point benefit ($p = 0.0007$; $N = 48$) to the intervention (coached) arm compared to the control (standard of care) arm over the two-year course of the intervention (**Supplemental Figure 4**). We performed a similar analysis with the Montreal Cognitive Assessment (MoCA), which showed similar results (**Supplemental Figure 6**). The MPI benefit was most evidenced as a fixed effect, rather than as an interactive term with time, suggesting that the trajectory of benefit was nonlinear. We fit a spline curve to the data to illustrate this non-linearity (**Figure 2**). This spline shows that most of the cognitive benefit occurs in the first year of intervention – perhaps during the first several months. Function as measured by the Functional Assessment Staging Test (FAST) is also significantly ameliorated in the intervention arm: linear regression showed a benefit to FAST ($p = 0.030$; **Supplemental Figure 7).** Therefore, both a measure of cognition (MPI) and a measure of function (FAST) ameliorated due to the COCOA intervention. This suggests that the COCOA intervention has broad multifaceted benefits across multiple systems – that the COCOA intervention is beneficial for overall brain health and for patient-oriented outcomes relevant to dementia.

3.B. Lemma 2: The COCOA intervention causes systemic molecular changes in the blood.

We expect that the COCOA intervention causes many effects in many organs and tissues, and that these are reflected in the blood. We analyze three classes of blood omics data: plasma proteomics, plasma metabolomics, and clinical labs. Collectively, we call all the measured molecules and metrics from these assays "analytes". Our global analyses encompassed 1461 analytes: 456 protein assays, 952 metabolites, and 53 clinical labs; 1447 of these are distinct. Our analysis of the aggregate cognitive trajectory (**Figure 2**) suggests that the response to intervention is non-linear, with the greatest divergence between the case and control trajectory happening during the first six months of the intervention. Therefore, we focus on the initial molecular physiological trajectory of participants. In addition to computing all-by-all correlations, we computed two statistics for each analyte. One statistic estimates the analyte's value as a biomarker for the intervention, and the other statistic estimates the analyte's value as a biomarker for the outcome. These two "intervention value" and "outcome value" statistics were computed as the significance of the slope of the regression between the analyte value and: (statistic 1) arm assignment or, (statistic 2) the overall MPI slope.



Figure 3. The COCOA intervention causes systemic changes in multiple molecular subsystems reflected in the blood. This visualization results from dimensionality reduction of the distances between all COCOA analytes as determined by absolute correlation distances. Significant nodes cluster, which implies that the effects of the COCOA intervention are not randomly spread across biological systems and may be targeted to systems specifically impacted by the intervention; random distribution would be expected if results were pure noise and no signal. The principal coordinates analysis (PCoA) multidimensional scaling (MDS) algorithm was used for dimensionality reduction. This algorithm incorporates all correlations; the resulting layout is dominated by the many effects of multiple small correlations, which may in aggregate contribute more to the placement of a node than the strongest correlations to that node. Larger nodes indicate significance of the effect of the COCOA intervention. Labels are added to nodes that are discussed in the main text of the manuscript. Urea appears twice, once as a clinical lab measurement, and once as a metabolite measurement.

To provide evidence for the causal effect of the COCOA intervention on the blood, **Figure 3** is an multidimensionally scaled (MDS) representation of all analytes. The significance of association between the case and control values for that analyte is represented by the size of the icon. The clustering of all significant analytes is astronomically significant by inspection. We also performed an analysis focused solely on



Figure 4. Bile acid, xenobiotic, and nitrogen metabolism pathways are likely altered by the COCOA intervention. The top pathways implicated by alterations in metabolites in response to the COCOA intervention are all consistent with prior knowledge that these pathways are impacted by diet and consumption of xenobiotics. Some of these pathways are also known to be affected by exercise and other components of the multimodal intervention. In order to leverage an existing workflow for pathway enrichment (Metaboanalyst, www.metaboanalyst.ca; Pang et al., 2021), for this figure only, we limited our analysis to the metabolite subset of all COCOA analytes. We divided metabolites into two groups, based on overall variance of all measurements of that analyte. High-variance analytes might have non-monotonic and non-linear trajectories; sampling such trajectories a few times a year could abet overconfidence. Because power to detect the effect of the intervention on a pathway depends on how well the components of that pathway can be detected by metabolite mass spectrometry and COCOA sampling frequency, failure to highly rank a pathway is not strong evidence for the absence of effects of the intervention on that pathway. (A) Pie charts indicate the category abundance of metabolites in each classification. (B) Pathway enrichment. (Left panel) Nitrogen metabolism pathways are enriched by low-variance metabolites; (Right panel) Bile acid and xenobiotic pathways are enriched by high-variance metabolites.

metabolite analytes (**Figure 4**). Considering these analyses together, analyte clustering must be due to the intervention. Therefore, the intervention causes manifold changes in analytes in the blood.

We are using a multimodal intervention. Although the desire is for this intervention to be as personalized as possible, many aspects of our interventions will have no effect on cognition. Furthermore, even if we know what node or subsystem we want to target (e.g., blood pressure), few interventions specifically target that element of the system. For example, a suboptimal exercise program might improve blood pressure but degrade sleep. In this manuscript, we seek to identify specific mediators that not only change in response to the COCOA intervention, but also improve cognition. We continue on this epistemological path in in the following lemmas.

3.C. Lemma 3: Molecular changes in the blood of COCOA participants are correlated with cognitive improvement.

For this lemma, we do not consider participant arm; that is, we ignore the case or control "label". We treat the COCOA trial as a cohort study. Individuals in the study differ in lifestyle for many reasons; they differ genetically and environmentally. The analytes most correlated with overall MPI slope are presented in **Table 3.** A primary "full" analysis considers all data, and a secondary "robust" analysis excludes outliers. Taken individually, the significance of any given analyte is weak. However, patterns emerge when these data are considered as an ensemble.

Xenobiotics, such as aspirin and food components (in some cases, "supplements"), are common among the most significant analytes in **Table 3**. The top two analytes are salicylate and N-acetylalliin (a xenobiotic metabolite that can be derived from garlic). Aspirin dose is a known predictor of cognitive trajectory in AD, at least in some contexts (Wattmo et al., 2011). Identification of these xenobiotics suggests that interventions other than the COCOA intervention may play a large role in cognitive improvement. The effect of these xenobiotics appears to be independent of the effect of the multimodal lifestyle intervention, and that therefore the best interventions may include combinations of both lifestyle and pharmacological/xenobiotic interventions. Consumption of particular pharmaceuticals or dietary chemicals that may be correlated with cognitive trajectory and may or may not be causal. Another non-exclusive explanation for the significance of these xenobiotics is that the presence of xenobiotics in the blood is a biomarker of attention and compliance to health advice — these xenobiotics may *correlate* with cognitive improvement but not *cause* cognitive improvement. A number of other analytes suggest other mechanisms, including those that may be targeted by the COCOA intervention.

3.D. Lemma 4: Some potential mediators & mechanisms may be shared by multiple individuals.

A potential mediator should (1) be influenced by the COCOA intervention, (2) influence cognition, and (3) the intervention effect should be in the same direction as the cognition effect. Therefore, an analyte must be identified as a top candidate in *both* lemma 2 and lemma 3 to be a potential mediator. Although our overarching hypothesis is that there are multiple mechanisms that may contribute personalizable therapies for AD, and that these may not be shared between particular individuals, we are confident there will be some that are shared between many individuals diagnosed with AD. If that were not the case, AD would no longer merit distinction as a named disease entity. Therefore, we aimed to detect shared or common molecular mediators of the



Figure 5. Candidate mediators of the COCOA intervention loosely cluster into two groups. Absolute correlation distances (edges) are shown between highly correlated COCOA analytes (nodes), based on changes between the first and second COCOA timepoints. One cluster including IL17D and IL18R1 may implicate an immune or inflammatory pathway(s) in mediation; another cluster may indicate metabolic pathway(s) in mediation. The non-random distribution of candidate mediators would be unlikely if they were all false positives (noise). This high-correlation network of all analytes is visualized via the Fruchterman-Reingold algorithm (Fruchterman & Reingold, 1991). This network includes the best edge for each node if that edge has a correlation of at least 0.55, and all edges with correlations of at least 0.85. This graph emphasizes the relationships and resulting correlation paths determined by the strongest most significant correlations between analytes, whereas the visualization in **Figure 3** is influenced by subtle effects from hundreds of weak correlations in the all-by-all analysis. Edge thickness ~ correlation; red indicates candidate mediator (**Table 5**). Labels are shifted radially out from the node they label to avoid obscuring network connectivity. The placement of albumin is arbitrary as it is not highly correlated to any other analyte.

COCOA intervention. To this end, we compared the top-ranked "robust" rankings of analytes that ranked highly in both (1) significance of response to the COCOA intervention (listed in **Table 2**, from lemma 2), and (2) significance of association with MPI slope (listed in **Table 3**, from lemma 3). These include both "full"-data ranking and "robust" rankings. The intersection between these lists is shown in **Table 4**. Three of the top seven

analytes (kynurenate, N-acetylkynurenine, N-acetyltryptophan) are associated with tryptophan metabolism. This coherence suggests that certain subsystems (in addition to individual analytes) might mediate the intervention.

There are four analytes that are nominally significant in both **Table 2** and **Table 3** (full analysis): propionylcarnitine, kynurenate, gamma-glutamyl-alpha-lysine, and albumin. This overlap of 4 is about the same as would be expected solely due to the simplest prediction from type I error (0.05 x 0.05 x 1461 = 3.6). Even though our p-values are approximate — and we likely lack power to detect changes in many of the analytes due to analyte idiosyncrasies (e.g. sparse consumption of certain xenobiotics), lack of much greater intersection than might be expected by chance weakens our argument that there is true signal in this list; our argument must rely on coherence and consistency considerations, which we describe in lemmas 6 & 7, below.

3.E. Lemma 5: Some potential mediators may be operating in only one or a few COCOA participants.

It is possible that some individuals may respond particularly well to a specific component of the COCOA intervention and/or via a specific molecular mediator. To this end, we compared the top-ranked "full" rankings of analytes that ranked highly in both (1) significance of response to the COCOA intervention (**Table 2**), and (2) significance of association with MPI slope (**Table 3**). Focus on the "full" rankings can identify analytes that have an importance driven primarily by a single or a few individuals. The intersection between these lists is shown in **Table 4**. Identification of these "personal" mediators in COCOA could lead to therapeutic targets available to a broader range of individuals. For example, there may be aspects of the intervention that were difficult to comply with, and only benefitted a few individuals able to comply. If we can better identify such intervention aspects, we may be able to drop compliance barriers or use alternative interventions to broaden the individuals that could leverage one or more of these personal mediators to drive cognitive benefit.

3.F. Lemma 6: Potential mediators and mechanisms are not random.

Random distribution of mechanistic attributes of potential mediators would be predicted if they all arose by chance. Non-random distribution argues against our list of potential mediators all being the result of experimental noise. To make our claim that COCOA mediators cluster cohesively, we computed correlations between all possible pairs of analytes. We then portrayed them with dimensionality reduction (**Figure 5**). The best candidate mediators cluster more than expected by chance, suggesting that there is a specific set of systems mediating the COCOA intervention's effect on cognition, and that the analytes within a system preferentially correlate with each other.

3.G. Lemma 7: Several identified mechanisms have considerable prior evidence for mediating AD interventions.

There are two lines of prior arguments that suggest that there are likely several if not many molecular mediators in the blood that might be identified by the COCOA study. First, a large number of mediators have been suggested in the literature, with varying degrees of evidence (e.g., Niranjan, 2013; Verdile et al., 2015). Although most of these devolve from studies of *causes* of AD, many are also likely to mediate ameliorative

treatments, presumably with an opposite direction of effect. Second, since we observe an effect of the COCOA intervention on cognition (lemma #1), there must be *some* mediator(s). Since the main COCOA modalities are diet (including xenobiotics) and exercise, and the vast majority of biological information conveyed by these modalities is conducted through the blood (after transduction through gut, muscle, heart, and other organs), there are likely several if not many mediators of their effects to be found in the blood. These arguments establish a high prior probability that a number of molecular mediators should be identifiable in the blood. We list all decent analyte mediator candidates from any of the above analyses (**Table 5**).

One might expect candidate mediators for ameliorating AD to be on a list of "well known suspects", or closely linked to such suspects in knowledge graphs. For example, one might expect a gene implicated by AD GWAS to have its gene product identified, or an analyte functionally associated with that gene. None of the candidate COCOA mediators intersect with a list of GWAS-implicated genes (Seto et al., 2021). Most mediators of multimodal interventions identified by COCOA target pathways are distinct from the pathways conveying genetic causes of AD. COCOA interventions might target (1) environmental causes of AD, and (2) pathways that treat but do not cause AD.

Subsystems. Chen et al. leveraged two-sample Mendelian randomization and GWAS summary statistics to explore the causal association between 486 metabolites and five neurodegenerative diseases (NDDs) including AD (Chen et al., 2021). They suggestively associated 164 metabolites with the risk of at least one neurodegenerative disease. They found metabolic pathways involved in NDDs, including "urea cycle" and "arginine biosynthesis", "purine metabolism", and "D-Glutamine and D-glutamate metabolism" for AD. They also found "phenylalanine, tyrosine and tryptophan biosynthesis" for ALS and MS. "Carnitine synthesis" was associated with FTD. Leao et al. (2021) show that the acylcarnitine subsystem differs between controls and Alzheimer's patients. Particular metabolites implicated in AD included urea and hexadecanedioate. Hexadecanedioate is also implicated in ischemic stroke (Sun et al., 2019), possibly mediated by its effects on blood pressure and/or its hypolipidemic, anti-obesity, or anti-diabetogenic properties. These pathways markedly overlap the pathways implicated by our current analysis. More broadly in the literature, all of these pathways have been implicated in ADRD. Some may potentiate AD by a vascular dementia diasthesis, and some are affected by APOE genotype.

4. Conclusions

We have shown that personalized multimodal lifestyle interventions can ameliorate cognitive trajectories in individuals on the AD spectrum. These interventions cause many changes in blood analytes. Several of these analytes are also correlated with cognitive amelioration. Analytes that are altered following the intervention ***and*** that are correlated with cognitive amelioration are candidate mediators. A mediator mechanistically (causally) conveys the influence of the intervention, propagating its information through biological pathways, to the brain, where it influences the final common pathways of ADRD pathophysiology, presumably on neurons and their

synapses. The mediators identified by COCOA implicate inflammatory and metabolic pathways that respond to changes in diet and possibly exercise. A number of candidate mediators (**Tables 4 & 5**) are anticorrelated with cognitive improvement. Reductions in blood levels of these mediators appear beneficial to cognition. Several of these are associated with food consumption, particularly highlighting nitrogen metabolism. Therefore, reducing caloric intake, possibly including protein restriction, may be a beneficial component of multimodal interventions in some individuals.

Our results have a number of broad implications. First, COCOA served well as a pilot trial. More trials should be modeled after COCOA's trial design. Such designs can generate new information, both testing well defined hypotheses and expanding the scope of inquiry into areas of pathophysiology that are less explored. Second, ADRD can be treated using mediators that are not directly related to the most prominent pathways (e.g., amyloid hypothesis) targeted by many pharmaceutics. Pathways to *treat* ADRD may be different than pathways that *cause* ADRD. Lifestyle treatments are likely to complement, not replace, pharmaceutical treatments. Both are likely to be part of many optimal personalized multimodal therapies. Third, lifestyle interventions should be emphasized in current treatment for all individuals on the ADRD spectrum. More funding for lifestyle interventions should be applied both to research and via payers for medical care.

There are numerous limitations to the COCOA trial. Briefly, we surveyed a large number of variables, and although some results were nominally statistically significant, these results would not be convincing on their own. The general conclusions are solid; specific conclusions about specific analytes are not. Correlation is not always causation. Correlation due to prospective randomization in an RCT is a very strong argument for causation. Thus we can be somewhat confident that the COCOA intervention causes broad molecular changes in the blood, and that the COCOA intervention improves the cognitive trajectory of AD. Although we provide some evidence for specific blood analytes that mediate this causation, there are alternative explanations for mediation. The same individuals who are compliant with diet and exercise advice may also be compliant with cognitive training, causing their blood omics to shift through their careful diet and exercise behaviors. Such shifts in blood omics could in theory be a red herring — the actual cause of cognitive improvement could be via neurocognitive mechanisms driven by the cognitive training elements of the multimodal intervention. However, biological plausibility — discussed below — suggests that blood does indeed convey at least some causality.

Biological plausibility & the rising importance of epistemology for the future of clinical trials. An important component of systems epistemology is *biological plausibility:* placing current research coherently and consistently in the context of previous research. More generally, new observations should be interpreted in the light of previous observations. Much of the argument we present today would not have been as strong a few years ago. In particular, at the time of trial design prior to beginning enrollment of participants, we could not have known the best methods of analysis or computed an exact power for the trial. These uncertainties create practical challenges for launching trials designed to take advantage of future knowledge. Such challenges must

be overcome for the full potential of research on complex diseases to flourish. Although not used extensively in our COCOA analyses to date, artificial intelligence (AI) is likely to potentiate the value of dense-data studies (Bughin et al., 2017; Naylor, 2017).

Final thoughts. A large amount of contextual knowledge concerning the roles, associations, mechanisms, and relationships of once-obscure metabolites is becoming available. Many of these implicate or highlight the roles of particular metabolites in response to diet and exercise. Dense-data trials are designed to be increasingly valuable as global knowledge accumulates. Such knowledge, particularly for metabolites, is increasing rapidly; the value of dense trials (both newly conducted and re-analyses of previously released data) will also increase rapidly.

Supplemental Table Legends

Supplemental Table 1. Data for all analytes. Each value is the difference between measurement at the baseline and first follow-up timepoint for an individual. Units are as described in Methods.

Supplemental Table 2. Population-level measures for specific analytes may be causally influenced by variation in specific genes. Many of the causal associations between genes and metabolites have been compiled (pheweb.org; Gagliano Taliun, et al., 2020). These associations relate some of the candidate mediators identified by COCOA. For example: KMO is a top influencer for both kynurenate and acetylkynurenine; SLCO1B1 is a top influencer for both hexadecanedioate and pregnenolone.

Contributions

Planning: LH, WS, JR; Analysis: JR, LE, DM, WS; Coaching: MR; Manuscript: All authors.

Acknowledgements

Deborah Fridman, Jennifer C. Lovejoy, Kathleen Jade, Laura Heim, Rachel Romansik, Adrienne Swietlikowski, Sheree Phillips, Maria Fischer, Dan Fischer, Lauren Dill, Michael Brant-Zawadzki, Sophiya Rajbhandari, Dale Bredesen, Mary Kay Ross, Amanda Wikan, Alex Lewis, Maia Kurnik, Christie Davidson, and Jennifer Eklund have inspired, managed, mooted, conceived, planned, participated, organized, supported, discussed, and/or analyzed aspects of the COCOA project or its precursors. COCOA would not have been possible without the participants, for whom we reserve the greatest acknowledgement and appreciation. Institutional support from Hoag Memorial Hospital Presbyterian was vital. Oregon Health & Science University's Bioinformatics and Computational Biomedicine program supported interns. Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A

complete listing of ADNI investigators can be found at adni.loni.usc.edu. Statue images (Figure 1): Folco Masi & Ziad Al Halabi (unsplash.com).

Data Availability

Data is available in **Supplemental Table 1**.

Declaration of interests

Dr. Shankle is an employee of EMBIC Corporation. Dr. Hara owns stock in EMBIC Corporation. There are no other conflicts of interest for any of the authors.

References

Abuelezz SA, Hendawy N. HMGB1/RAGE/TLR4 axis and glutamate as novel targets for PCSK9 inhibitor in high fat cholesterol diet induced cognitive impairment and amyloidosis. Life Sci. 2021 May 15;273:119310. doi: 10.1016/j.lfs.2021.119310. Epub 2021 Mar 2. PMID: 33667517.

Aisen PS, Jimenez-Maggiora GA, Rafii MS, Walter S, Raman R. Early-stage Alzheimer disease: getting trial-ready. Nat Rev Neurol. 2022 Jul;18(7):389-399. doi: 10.1038/s41582-022-00645-6. Epub 2022 Apr 4. PMID: 35379951; PMCID: PMC8978175.

Alaamery M, Albesher N, Aljawini N, Alsuwailm M, Massadeh S, Wheeler MA, Chao CC, Quintana FJ. Role of sphingolipid metabolism in neurodegeneration. J Neurochem. 2021 Jul;158(1):25-35. doi: 10.1111/jnc.15044. Epub 2020 Jul 3. PMID: 32402091; PMCID: PMC7665988.

Alzheimer's Association. Basic Resources on Alzheimer’s for Primary Care Physicians. Alzheimer’s Association Green-Field Library. 2019.

Alzheimer’s Association. 2022 Alzheimer's disease facts and figures. Alzheimers Dement. 2022 Apr;18(4):700-789. doi: 10.1002/alz.12638. Epub 2022 Mar 14. PMID: 35289055.

Babygirija et al. Beneficial effects of protein restriction on metabolic health, cognitive function and neuropathology in a mouse model of Alzheimer’s disease. AAIC 2022.

Babygirija R, Lamming DW. The regulation of healthspan and lifespan by dietary amino acids. Transl Med Aging. 2021;5:17-30. doi: 10.1016/j.tma.2021.05.001. Epub 2021 May 24. PMID: 34263088; PMCID: PMC8277109.

Baumgart M, Snyder HM, Carrillo MC, Fazio S, Kim H, Johns H. Summary of the evidence on modifiable risk factors for cognitive decline and dementia: A population-based perspective. Alzheimers Dement. 2015 Jun;11(6):718-26. doi: 10.1016/j.jalz.2015.05.016. Epub 2015 Jun 1. PMID: 26045020.

Bughin Hazan Ramaswamy et al. Artificial intelligence the next digital frontier? June 2017. McKinsey Global Institute.

Bullock R, Touchon J, Bergman H, Gambina G, He Y, Rapatz G, Nagel J, Lane R. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Curr Med Res Opin. 2005 Aug;21(8):1317-27. doi: 10.1185/030079905X56565. PMID: 16083542.

Burns A, Gauthier S, Perdomo C. Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease. Int J Geriatr Psychiatry. 2007 Aug;22(8):806-12. doi: 10.1002/gps.1746. PMID: 17199235.

Busch KL. Units in mass spectrometry. 2001. Spectroscopy 16(11):28-31.

Cappuccio G, Pinelli M, Alagia M, Donti T, Day-Salvatore DL, Veggiotti P, De Giorgis V, Lunghi S, Vari MS, Striano P, Brunetti-Pierri N, Kennedy AD, Elsea SH. Biochemical phenotyping unravels novel metabolic

abnormalities and potential biomarkers associated with treatment of GLUT1 deficiency with ketogenic diet. PLoS One. 2017 Sep 29;12(9):e0184022. doi: 10.1371/journal.pone.0184022. PMID: 28961260; PMCID: PMC5621665.

Chen H, Qiao J, Wang T, Shao Z, Huang S, Zeng P. Assessing Causal Relationship Between Human Blood Metabolites and Five Neurodegenerative Diseases With GWAS Summary Statistics. Front Neurosci. 2021 Dec 9;15:680104. doi: 10.3389/fnins.2021.680104. PMID: 34955704; PMCID: PMC8695771.

Coon DW, Gómez-Morales A. Modifiable Risk Factors for Brain Health and Dementia and Opportunities for Intervention: A Brief Review. Clin Gerontol. 2022 Aug 22:1-12. doi: 10.1080/07317115.2022.2114396. Epub ahead of print. PMID: 35996225.

Costa AC, Joaquim HPG, Forlenza OV, Gattaz WF, Talib LL. Three plasma metabolites in elderly patients differentiate mild cognitive impairment and Alzheimer's disease: a pilot study. Eur Arch Psychiatry Clin Neurosci. 2020 Jun;270(4):483-488. doi: 10.1007/s00406-019-01034-9. Epub 2019 Jun 19. PMID: 31218445.

Costa M, Horrillo R, Ortiz AM, Pérez A, Mestre A, Ruiz A, Boada M, Grancha S. Increased Albumin Oxidation in Cerebrospinal Fluid and Plasma from Alzheimer's Disease Patients. J Alzheimers Dis. 2018;63(4):1395-1404. doi: 10.3233/JAD-180243. PMID: 29782326; PMCID: PMC6004933.

Courtemanche H, Bigot E, Pichelin M, Guyomarch B, Boutoleau-Bretonnière C, Le May C, Derkinderen P, Cariou B. PCSK9 Concentrations in Cerebrospinal Fluid Are Not Specifically Increased in Alzheimer's Disease. J Alzheimers Dis. 2018;62(4):1519-1525. doi: 10.3233/JAD-170993. PMID: 29562508.

Daly T. Are trailblazing trials for reducing cognitive decline putting the cart before the horse? Alzheimers Dement (N Y). 2022 Jun 13;8(1):e12298. doi: 10.1002/trc2.12298. PMID: 35733646; PMCID: PMC9191824.

Devi S, Pasanna RM, Nadiger N, Ghosh S, Kurpad AV, Mukhopadhyay A. Variability of human fasted venous plasma metabolomic profiles with tourniquet induced hemostasis. Sci Rep. 2021 Dec 27;11(1):24458. doi: 10.1038/s41598-021-03665-2. PMID: 34961768; PMCID: PMC8712516.

Dhana K, Evans DA, Rajan KB, Bennett DA, Morris MC. Healthy lifestyle and the risk of Alzheimer dementia: Findings from 2 longitudinal studies. Neurology. 2020 Jul 28;95(4):e374-e383. doi: 10.1212/WNL.0000000000009816. Epub 2020 Jun 17. PMID: 32554763; PMCID: PMC7455318.

Dubois B, Feldman HH, Jacova C, et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 2010;9(11):1118-1127. doi:10.1016/S1474-4422(10)70223-4

Earls JC, Rappaport N, Heath L, Wilmanski T, Magis AT, Schork NJ, Omenn GS, Lovejoy J, Hood L, Price ND. Multi-Omic Biological Age Estimation and Its Correlation With Wellness and Disease Phenotypes: A Longitudinal Study of 3,558 Individuals. J Gerontol A Biol Sci Med Sci. 2019 Nov 13;74(Suppl_1):S52-S60. doi: 10.1093/gerona/glz220. PMID: 31724055; PMCID: PMC6853785.

Fedak KM, Bernal A, Capshaw ZA, Gross S. Applying the Bradford Hill criteria in the 21st century: how data integration has changed causal inference in molecular epidemiology. Emerg Themes Epidemiol. 2015;12:14. Published 2015 Sep 30. doi:10.1186/s12982-015-0037-4.

Fruchterman T, Reingold E. Graph drawing by force-directed placement. Software: Practice and Experience. 1991. 21(11):1129-1164.

Gagliano Taliun SA, VandeHaar P, Boughton AP, Welch RP, Taliun D, Schmidt EM, Zhou W, Nielsen JB, Willer CJ, Lee S, Fritsche LG, Boehnke M, Abecasis GR. Exploring and visualizing large-scale genetic associations by using PheWeb. Nat Genet. 2020 Jun;52(6):550-552. doi: 10.1038/s41588-020-0622-5. PMID: 32504056; PMCID: PMC7754083.

Hannan MA, Dash R, Sohag AAM, Haque MN, Moon IS. Neuroprotection Against Oxidative Stress: Phytochemicals Targeting TrkB Signaling and the Nrf2-ARE Antioxidant System. Front Mol Neurosci. 2020 Jul 2;13:116. doi: 10.3389/fnmol.2020.00116. PMID: 32714148; PMCID: PMC7346762.

He XY, Isaacs C, Yang SY. Roles of Mitochondrial 17β-Hydroxysteroid Dehydrogenase Type 10 in Alzheimer's Disease. J Alzheimers Dis. 2018;62(2):665-673. doi: 10.3233/JAD-170974. PMID: 29480196.

Hendrix, SB et al. Not sexy enough: the uphill battle faced by non-traditional treatments in the U.S. despite having the most compelling AD results to date. AAIC 2022.

Herrmann N, Lanctôt KL, Hogan DB. Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012. Alzheimers Res Ther. 2013 Jul 8;5(Suppl 1):S5. doi: 10.1186/alzrt201. Epub 2013 Jul 8. PMID: 24565367; PMCID: PMC3980908.

Ioannidis JP. Why most discovered true associations are inflated. Epidemiology. 2008 Sep;19(5):640-8. doi: 10.1097/EDE.0b013e31818131e7. Erratum in: Epidemiology. 2009 Jul;20(4):629. PMID: 18633328.

Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14(4):535-562. doi:10.1016/j.jalz.2018.02.018.

Jewell DE, Jackson MI. Dietary Fatty Acids Change Circulating Fatty Acids, Microbial Putrefactive Postbiotics and Betaine Status in the Cat. Animals (Basel). 2020 Dec 6;10(12):2310. doi: 10.3390/ani10122310. PMID: 33291310; PMCID: PMC7762147.

Kaplanski G. Interleukin-18: Biological properties and role in disease pathogenesis. Immunol Rev. 2018 Jan;281(1):138-153. doi: 10.1111/imr.12616. PMID: 29247988; PMCID: PMC7165732.

Khodorova NV, Rietman A, Rutledge DN, Schwarz J, Piedcoq J, Pilard S, Siebelink E, Kok FJ, Tomé D, Mensink M, Azzout-Marniche D. Urinary Medium-Chained Acyl-Carnitines Sign High Caloric Intake whereas Short-Chained Acyl-Carnitines Sign High -Protein Diet within a High-Fat, Hypercaloric Diet in a Randomized Crossover Design Dietary Trial. Nutrients. 2021 Apr 3;13(4):1191. doi: 10.3390/nu13041191. PMID: 33916877; PMCID: PMC8066704.

Killingsworth J, Sawmiller D, Shytle RD. Propionate and Alzheimer's Disease. Front Aging Neurosci. 2021 Jan 11;12:580001. doi: 10.3389/fnagi.2020.580001. PMID: 33505301; PMCID: PMC7831739.

Kocatürk RR, Temizyürek A, Özcan ÖÖ, Ergüzel TT, Karahan M, Konuk M, Tarhan N. Effect of nutritional supports on malnutrition, cognition, function and biomarkers of Alzheimer's disease: a systematic review. Int J Neurosci. 2022 Jul 3:1-19. doi: 10.1080/00207454.2022.2079506. Epub ahead of print. PMID: 35686376.

Lakens D. Pandemic researchers - recruit your own best critics. Nature. 2020 May;581(7807):121. doi: 10.1038/d41586-020-01392-8. PMID: 32393923.

Leng F, Edison P. Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here? Nat Rev Neurol. 2021 Mar;17(3):157-172. doi: 10.1038/s41582-020-00435-y. Epub 2020 Dec 14. PMID: 33318676.

Li X, Bechara R, Zhao J, McGeachy MJ, Gaffen SL. IL-17 receptor-based signaling and implications for disease. Nat Immunol. 2019 Dec;20(12):1594-1602. doi: 10.1038/s41590-019-0514-y. Epub 2019 Nov 19. PMID: 31745337; PMCID: PMC6943935.

Liu X, Sun S, Liu D. IL-17D: A Less Studied Cytokine of IL-17 Family. Int Arch Allergy Immunol. 2020;181(8):618-623. doi: 10.1159/000508255. Epub 2020 Jun 9. PMID: 32516792.

Llewellyn DJ, Langa KM, Friedland RP, Lang IA. Serum albumin concentration and cognitive impairment. Curr Alzheimer Res. 2010 Feb;7(1):91-6. doi: 10.2174/156720510790274392. PMID: 20205675; PMCID: PMC2886725.

Lustbader JW, Cirilli M, Lin C, Xu HW, Takuma K, Wang N, Caspersen C, Chen X, Pollak S, Chaney M, Trinchese F, Liu S, Gunn-Moore F, Lue LF, Walker DG, Kuppusamy P, Zewier ZL, Arancio O, Stern D, Yan SS, Wu H. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science. 2004 Apr 16;304(5669):448-52. doi: 10.1126/science.1091230. PMID: 15087549.

Maldonado C, Guevara N, Queijo C, González R, Fagiolino P, Vázquez M. Carnitine and/or Acetylcarnitine Deficiency as a Cause of Higher Levels of Ammonia. Biomed Res Int. 2016;2016:2920108. doi: 10.1155/2016/2920108. Epub 2016 Feb 21. PMID: 26998483; PMCID: PMC4779505.

Mazura AD, Ohler A, Storck SE, Kurtyka M, Scharfenberg F, Weggen S, Becker-Pauly C, Pietrzik CU. PCSK9 acts as a key regulator of Aβ clearance across the blood-brain barrier. Cell Mol Life Sci. 2022 Mar 27;79(4):212. doi: 10.1007/s00018-022-04237-x. PMID: 35344086; PMCID: PMC8960591.

McEwen SC, Merrill DA, Bramen J, Porter V, Panos S, Kaiser S, Hodes J, Ganapathi A, Bell L, Bookheimer T, Glatt R, Rapozo M, Ross MK, Price ND, Kelly D, Funk CC, Hood L, Roach JC. A systems-biology clinical trial of a personalized multimodal lifestyle intervention for early Alzheimer's disease. Alzheimers Dement (N Y). 2021 Jul 20;7(1):e12191. doi: 10.1002/trc2.12191. PMID: 34295960; PMCID: PMC8290633.

Menendez-Gonzalez M, Gasparovic C. Albumin Exchange in Alzheimer's Disease: Might CSF Be an Alternative Route to Plasma? Front Neurol. 2019 Oct 18;10:1036. doi: 10.3389/fneur.2019.01036. PMID: 31681137; PMCID: PMC6813234.

Menni C, Graham D, Kastenmüller G, Alharbi NH, Alsanosi SM, McBride M, Mangino M, Titcombe P, Shin SY, Psatha M, Geisendorfer T, Huber A, Peters A, Wang-Sattler R, Xu T, Brosnan MJ, Trimmer J, Reichel C, Mohney RP, Soranzo N, Edwards MH, Cooper C, Church AC, Suhre K, Gieger C, Dominiczak AF, Spector TD, Padmanabhan S, Valdes AM. Metabolomic identification of a novel pathway of blood pressure regulation involving hexadecanedioate. Hypertension. 2015 Aug;66(2):422-9. doi: 10.1161/HYPERTENSIONAHA.115.05544. Epub 2015 Jun 1. PMID: 26034203; PMCID: PMC4490909.

Miles FL, Orlich MJ, Mashchak A, Chandler PD, Lampe JW, Duerksen-Hughes P, Fraser GE. The Biology of Veganism: Plasma Metabolomics Analysis Reveals Distinct Profiles of Vegans and Non-Vegetarians in the Adventist Health Study-2 Cohort. Nutrients. 2022 Feb 8;14(3):709. doi: 10.3390/nu14030709. PMID: 35277064; PMCID: PMC8839915.

Milošević M, Arsić A, Cvetković Z, Vučić V. Memorable Food: Fighting Age-Related Neurodegeneration by Precision Nutrition. Front Nutr. 2021 Aug 5;8:688086. doi: 10.3389/fnut.2021.688086. PMID: 34422879; PMCID: PMC8374314.

Naylor M. (2017). Key Technological Disruptors. In: Insurance Transformed. Palgrave Studies in Financial Services Technology. Palgrave Macmillan, Cham. https://doi.org/10.1007/978-3-319-63835-5_2.

Nayor M, Shah RV, Miller PE, Blodgett JB, Tanguay M, Pico AR, Murthy VL, Malhotra R, Houstis NE, Deik A, Pierce KA, Bullock K, Dailey L, Velagaleti RS, Moore SA, Ho JE, Baggish AL, Clish CB, Larson MG, Vasan RS, Lewis GD. Metabolic Architecture of Acute Exercise Response in Middle-Aged Adults in the Community. Circulation. 2020 Nov 17;142(20):1905-1924. doi: 10.1161/CIRCULATIONAHA.120.050281. Epub 2020 Sep 15. PMID: 32927962; PMCID: PMC8049528.

Ngandu T, Lehtisalo J, Korkki S, Solomon A, Coley N, Antikainen R, Bäckman L, Hänninen T, Lindström J, Laatikainen T, Paajanen T, Havulinna S, Peltonen M, Neely AS, Strandberg T, Tuomilehto J, Soininen H, Kivipelto M. The effect of adherence on cognition in a multidomain lifestyle intervention (FINGER). Alzheimers Dement. 2022 Jul;18(7):1325-1334. doi: 10.1002/alz.12492. Epub 2021 Oct 20. PMID: 34668644.

Niranjan R. Molecular basis of etiological implications in Alzheimer's disease: focus on neuroinflammation. Mol Neurobiol. 2013 Dec;48(3):412-28. doi: 10.1007/s12035-013-8428-4. Epub 2013 Feb 19. PMID: 23420079.

Pang Z, Chong J, Zhou G, de Lima Morais DA, Chang L, Barrette M, Gauthier C, Jacques PÉ, Li S, Xia J. MetaboAnalyst 5.0: narrowing the gap between raw spectra and functional insights. Nucleic Acids Res. 2021 Jul 2;49(W1):W388-W396. doi: 10.1093/nar/gkab382. PMID: 34019663; PMCID: PMC8265181.

Paquette M, Saavedra YGL, Poirier J, Théroux L, Dea D, Baass A, Dufour R. Loss-of-Function PCSK9 Mutations Are Not Associated With Alzheimer Disease. J Geriatr Psychiatry Neurol. 2018 Mar;31(2):90-96. doi: 10.1177/0891988718764330. Epub 2018 Mar 21. PMID: 29562810.

Pey P, Pearce RK, Kalaitzakis ME, Griffin WS, Gentleman SM. Phenotypic profile of alternative activation marker CD163 is different in Alzheimer's and Parkinson's disease. Acta Neuropathol Commun. 2014 Feb 14;2:21. doi: 10.1186/2051-5960-2-21. PMID: 24528486; PMCID: PMC3940003.

Picard C, Poirier A, Bélanger S, Labonté A, Auld D, Poirier J; PREVENT-AD Research Group. Proprotein convertase subtilisin/kexin type 9 (PCSK9) in Alzheimer's disease: A genetic and proteomic multi-cohort study. PLoS One. 2019 Aug 22;14(8):e0220254. doi: 10.1371/journal.pone.0220254. PMID: 31437157; PMCID: PMC6705826.

Raket LL. A new approach for estimating and quantifying disease-modification in Alzheimer's disease clinical trials. 2022. AAIC, San Diego.

Ramdane S. Plasma Urea in Alzheimer's Disease: An Observational Study. 2017. AAIC poster presentation P3-247 p.1035.

Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology. 2000 Jun 27;54(12):2261-8. doi: 10.1212/wnl.54.12.2261. PMID: 10881250.

Reisberg B. Dementia: a systematic approach to identifying reversible causes. Geriatrics. 1986 Apr;41(4):30-46. PMID: 3949165.

Roach JC, Hara J, Edens L, Sophiya Rajbhandari, Lauren Dill, Rachel Romansik, Molly K. Rapozo, Cory Funk, Kathleen Jade, David A. Merrill, Jennifer E. Bramen, Stella E. Panos, Verna R. Porter, Richelin V. Dye, Aarthi S. Ganapathi, John F. Hodes, Colby B. Slyapich, Ryan M. Glatt, Claudia L. Wong, Dennis Fortier and William R Shankle. Frequent Cognitive Tests Increase Power for Alzheimer's Disease Clinical Trials. AAIC 2022.

Roach JC, Hara J, Fridman D, Lovejoy JC, Jade K, Heim L, Romansik R, Swietlikowski A, Phillips S, Rapozo MK, Shay MA, Fischer D, Funk C, Dill L, Brant-Zawadzki M, Hood L, Shankle WR. The Coaching for Cognition in Alzheimer's (COCOA) trial: Study design. Alzheimers Dement (N Y). 2022 Jul 26;8(1):e12318. doi: 10.1002/trc2.12318. PMID: 35910672; PMCID: PMC9322829.

Roach JC, Hodes JF, Funk CC, Shankle WR, Merrill DA, Hood L, Bramen J. Dense data enables twenty-first century clinical trials. Alzheimers Dement (N Y). 2022 Jun 13;8(1):e12297. doi: 10.1002/trc2.12297. PMID: 35733645; PMCID: PMC9191823.

Roberts ES, Masliah E, Fox HS. CD163 identifies a unique population of ramified microglia in HIV encephalitis (HIVE). J Neuropathol Exp Neurol. 2004 Dec;63(12):1255-64. doi: 10.1093/jnen/63.12.1255. PMID: 15624762.

Roe CR, Millington DS, Maltby DA, Bohan TP, Hoppel CL. L-carnitine enhances excretion of propionyl coenzyme A as propionylcarnitine in propionic acidemia. J Clin Invest. 1984 Jun;73(6):1785-8. doi: 10.1172/JCI111387. PMID: 6725560; PMCID: PMC437091.

Rosenberg NA, Pritchard JK, Weber JL, Cann HM, Kidd KK, Zhivotovsky LA, Feldman MW. Genetic structure of human populations. Science. 2002 Dec 20;298(5602):2381-5. doi: 10.1126/science.1078311. PMID: 12493913.

Ross MK, Raji C, Lokken KL, Bredesen DE, Roach JC, Funk CC, Price N, Rappaport N, Hood L, Heath JR. Case Study: A Precision Medicine Approach to Multifactorial Dementia and Alzheimer's Disease. J Alzheimers Dis Parkinsonism. 2021;11(Suppl 5):018. Epub 2021 Aug 25. PMID: 35237464; PMCID: PMC8887953.

Rossini PM, Miraglia F, Vecchio F. Early dementia diagnosis, MCI-to-dementia risk prediction, and the role of machine learning methods for feature extraction from integrated biomarkers, in particular for EEG signal analysis. Alzheimers Dement. 2022 Apr 7. doi: 10.1002/alz.12645. Epub ahead of print. PMID: 35388959.

Saddawi-Konefka R, Seelige R, Gross ET, Levy E, Searles SC, Washington A Jr, Santosa EK, Liu B, O'Sullivan TE, Harismendy O, Bui JD. Nrf2 Induces IL-17D to Mediate Tumor and Virus Surveillance. Cell Rep. 2016 Aug 30;16(9):2348-58. doi: 10.1016/j.celrep.2016.07.075. Epub 2016 Aug 18. PMID: 27545889; PMCID: PMC5007173.

Salloway S, Farlow M, McDade E, Clifford DB, Wang G, Llibre-Guerra JJ, Hitchcock JM, Mills SL, Santacruz AM, Aschenbrenner AJ, Hassenstab J, Benzinger TLS, Gordon BA, Fagan AM, Coalier KA, Cruchaga C, Goate AA, Perrin RJ, Xiong C, Li Y, Morris JC, Snider BJ, Mummery C, Surti GM, Hannequin D, Wallon D,

Berman SB, Lah JJ, Jimenez-Velazquez IZ, Roberson ED, van Dyck CH, Honig LS, Sánchez-Valle R, Brooks WS, Gauthier S, Galasko DR, Masters CL, Brosch JR, Hsiung GR, Jayadev S, Formaglio M, Masellis M, Clarnette R, Pariente J, Dubois B, Pasquier F, Jack CR Jr, Koeppe R, Snyder PJ, Aisen PS, Thomas RG, Berry SM, Wendelberger BA, Andersen SW, Holdridge KC, Mintun MA, Yaari R, Sims JR, Baudler M, Delmar P, Doody RS, Fontoura P, Giacobino C, Kerchner GA, Bateman RJ; Dominantly Inherited Alzheimer Network–Trials Unit. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. Nat Med. 2021 Jul;27(7):1187-1196. doi: 10.1038/s41591-021-01369-8. Epub 2021 Jun 21. PMID: 34155411; PMCID: PMC8988051.

Scapagnini G, Vasto S, Abraham NG, Caruso C, Zella D, Fabio G. Modulation of Nrf2/ARE pathway by food polyphenols: a nutritional neuroprotective strategy for cognitive and neurodegenerative disorders. Mol Neurobiol. 2011 Oct;44(2):192-201. doi: 10.1007/s12035-011-8181-5. Epub 2011 Apr 19. Erratum in: Mol Neurobiol. 2011 Oct;44(2):202. Sonya, Vasto [corrected to Vasto, Sonya]; Nader, Abraham G [corrected to Abraham, Nader G]; Calogero, Caruso [corrected to Caruso, Calogero]. PMID: 21499987; PMCID: PMC5554938.

Seto M, Weiner RL, Dumitrescu L, Hohman TJ. Protective genes and pathways in Alzheimer's disease: moving towards precision interventions. Mol Neurodegener. 2021 Apr 29;16(1):29. doi: 10.1186/s13024-021-00452-5. PMID: 33926499; PMCID: PMC8086309.

Shankle WR, Mangrola T, Chan T, Hara J. Development and validation of the Memory Performance Index: reducing measurement error in recall tests. Alzheimers Dement. 2009 Jul;5(4):295-306. doi: 10.1016/j.jalz.2008.11.001. PMID: 19560100.

Shippy DC, Wilhelm C, Viharkumar PA, Raife TJ, Ulland TK. β-Hydroxybutyrate inhibits inflammasome activation to attenuate Alzheimer's disease pathology. J Neuroinflammation. 2020 Sep 21;17(1):280. doi: 10.1186/s12974-020-01948-5. PMID: 32958021; PMCID: PMC7507727.

Solianik R, Schwieler L, Trepci A, Erhardt S, Brazaitis M. Two-day fasting affects kynurenine pathway with additional modulation of short-term whole-body cooling: a quasi-randomised crossover trial. Br J Nutr. 2022 Jul 6:1-8. doi: 10.1017/S0007114522002069. Epub ahead of print. PMID: 35791050.

Sun D, Tiedt S, Yu B, Jian X, Gottesman RF, Mosley TH, Boerwinkle E, Dichgans M, Fornage M. A prospective study of serum metabolites and risk of ischemic stroke. Neurology. 2019 Apr 16;92(16):e1890-e1898. doi: 10.1212/WNL.0000000000007279. Epub 2019 Mar 13. PMID: 30867269; PMCID: PMC6550501.

Theiler J. (2004). Combining statistical tests by multiplying p-values. Astrophysics and Radiation Measurements Group, NIS-2.

Toups K, Hathaway A, Gordon D, Chung H, Raji C, Boyd A, Hill BD, Hausman-Cohen S, Attarha M, Chwa WJ, Jarrett M, Bredesen DE. Precision Medicine Approach to Alzheimer's Disease: Successful Pilot Project. J Alzheimers Dis. 2022;88(4):1411-1421. doi: 10.3233/JAD-215707. PMID: 35811518.

Tynkkynen J, Chouraki V, van der Lee SJ, Hernesniemi J, Yang Q, Li S, Beiser A, Larson MG, Sääksjärvi K, Shipley MJ, Singh-Manoux A, Gerszten RE, Wang TJ, Havulinna AS, Würtz P, Fischer K, Demirkan A, Ikram MA, Amin N, Lehtimäki T, Kähönen M, Perola M, Metspalu A, Kangas AJ, Soininen P, Ala-Korpela M, Vasan RS, Kivimäki M, van Duijn CM, Seshadri S, Salomaa V. Association of branched-chain amino acids and other circulating metabolites with risk of incident dementia and Alzheimer's disease: A prospective study in eight cohorts. Alzheimers Dement. 2018 Jun;14(6):723-733. doi: 10.1016/j.jalz.2018.01.003. Epub 2018 Mar 6. PMID: 29519576; PMCID: PMC6082422.

Varma VR, Oommen AM, Varma S, Casanova R, An Y, Andrews RM, O'Brien R, Pletnikova O, Troncoso JC, Toledo J, Baillie R, Arnold M, Kastenmueller G, Nho K, Doraiswamy PM, Saykin AJ, Kaddurah-Daouk R, Legido-Quigley C, Thambisetty M. Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: A targeted metabolomics study. PLoS Med. 2018 Jan 25;15(1):e1002482. doi: 10.1371/journal.pmed.1002482. PMID: 29370177; PMCID: PMC5784884.

Verdile G, Keane KN, Cruzat VF, Medic S, Sabale M, Rowles J, Wijesekara N, Martins RN, Fraser PE, Newsholme P. Inflammation and Oxidative Stress: The Molecular Connectivity between Insulin Resistance, Obesity, and Alzheimer's Disease. Mediators Inflamm. 2015;2015:105828. doi: 10.1155/2015/105828. Epub 2015 Nov 26. PMID: 26693205; PMCID: PMC4674598.

Wang Y, Shang Y, Mishra A, Bacon E, Yin F, Brinton R. Midlife Chronological and Endocrinological Transitions in Brain Metabolism: System Biology Basis for Increased Alzheimer's Risk in Female Brain. Sci Rep. 2020 May 22;10(1):8528. doi: 10.1038/s41598-020-65402-5. PMID: 32444841; PMCID: PMC7244485.

Wattmo C, Wallin AK, Londos E, Minthon L. Predictors of long-term cognitive outcome in Alzheimer's disease. Alzheimers Res Ther. 2011 Jul 20;3(4):23. doi: 10.1186/alzrt85. PMID: 21774798; PMCID: PMC3226278.

Wood; Amy K. Glen; Lindsey G. Kvarfordt; Finn Womack; Liliana Acevedo; Timothy S. Yoon; Chunyu Ma; Veronica Flores; Meghamala Sinha; Yodsawalai Chodpathumwan; Arash Termehchy; Jared C. Roach; Luis Mendoza; Andrew S. Hoffman; Eric W. Deutsch; David Koslicki; Stephen A. Ramsey. RTX-KG2: a system for building a semantically standardized knowledge graph for translational biomedicine. BMC Bioinformatics. Submitted 2022.

Yan SD, Fu J, Soto C, Chen X, Zhu H, Al-Mohanna F, Collison K, Zhu A, Stern E, Saido T, Tohyama M, Ogawa S, Roher A, Stern D. An intracellular protein that binds amyloid-beta peptide and mediates neurotoxicity in Alzheimer's disease. Nature. 1997 Oct 16;389(6652):689-95. doi: 10.1038/39522. PMID: 9338779.

Yang SY, He XY, Miller D. HSD17B10: a gene involved in cognitive function through metabolism of isoleucine and neuroactive steroids. Mol Genet Metab. 2007 Sep-Oct;92(1-2):36-42. doi: 10.1016/j.ymgme.2007.06.001. Epub 2007 Jul 6. PMID: 17618155.

Yatsunenko T, Rey FE, Manary MJ, Trehan I, Dominguez-Bello MG, Contreras M, Magris M, Hidalgo G, Baldassano RN, Anokhin AP, Heath AC, Warner B, Reeder J, Kuczynski J, Caporaso JG, Lozupone CA, Lauber C, Clemente JC, Knights D, Knight R, Gordon JI. Human gut microbiome viewed across age and geography. Nature. 2012 May 9;486(7402):222-7. doi: 10.1038/nature11053. PMID: 22699611; PMCID: PMC3376388.

Yin X, Chan LS, Bose D, Jackson AU, VandeHaar P, Locke AE, Fuchsberger C, Stringham HM, Welch R, Yu K, Fernandes Silva L, Service SK, Zhang D, Hector EC, Young E, Ganel L, Das I, Abel H, Erdos MR, Bonnycastle LL, Kuusisto J, Stitziel NO, Hall IM, Wagner GR; FinnGen, Kang J, Morrison J, Burant CF, Collins FS, Ripatti S, Palotie A, Freimer NB, Mohlke KL, Scott LJ, Wen X, Fauman EB, Laakso M, Boehnke M. Genome-wide association studies of metabolites in Finnish men identify disease-relevant loci. Nat Commun. 2022 Mar 28;13(1):1644. doi: 10.1038/s41467-022-29143-5. PMID: 35347128; PMCID: PMC8960770.

Zwilling D, Huang SY, Sathyasaikumar KV, Notarangelo FM, Guidetti P, Wu HQ, Lee J, Truong J, Andrews-Zwilling Y, Hsieh EW, Louie JY, Wu T, Scearce-Levie K, Patrick C, Adame A, Giorgini F, Moussaoui S, Laue G, Rassoulpour A, Flik G, Huang Y, Muchowski JM, Masliah E, Schwarcz R, Muchowski PJ. Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell. 2011 Jun 10;145(6):863-74. doi: 10.1016/j.cell.2011.05.020. PMID: 21640374; PMCID: PMC3118409.

Characteristic	**Control (n=22)**	**Coaching (n=31)**
Female, n (%)	8 (36%)	10 (32%)
Age, mean years (range)	73.5 (58-89+)	75.5 (58-89+)
MPI score, mean (range)	42.5 (13-64)	40.2 (15-63)
FAST score, mean (range)	3.0 (2-4)	3.2 (2-4)
Race, fraction White (%)	22/22 (100%)	27/31 (84%)
BMI, mean (range)	26.7 (21, 34)	25.6 (20, 34)
Maximum education completed		
High school/GED	2	2
Some college/tech school	1	6
Associate and/or bachelor's	11	14
Master's/doctorate/professional	5	6
No response	3	3

Table 1. Baseline participant characteristics. Demographic attributes were balanced between the two arms of the COCOA trial (N=53 completed baseline assessments).

Analyte ID	Name	Symbol or Pathway or System or Category	p-value (full)	p-value (robust)	Rank (full)	Rank (robust)	Effect Size (full)	Effect Size (robust)
CVD2_P40225	thrombopoietin	THPO	0.0002	0.0007	1	5	1.10	0.89
100001540	pyroglutamine	Glutamate Metabolism	0.0003	0.0008	2	6	-1.23	-0.95
100008993	1-palmitoyl-2-arachidonoyl-GPI (16:0/20:4)	Phospholipid Metabolism	0.0004	0.0014	3	8	-0.91	-0.74
100020219	3-formylindole	Food Component/Plant	0.0007	0.0004	4	1	-0.98	-0.94
100009181	1-stearoyl-2-oleoyl-GPI (18:0/18:1)	Phospholipid Metabolism	0.0007	0.0007	5	3	-1.33	-1.33
100001026	galactonate	Fructose, Mannose and Galactose Metabolism	0.0011	0.0007	6	4	-6.76	-6.39
566	valine	Leucine, Isoleucine and Valine Metabolism	0.0014	0.0014	7	7	-0.43	-0.43
98	kynurenate	Tryptophan Metabolism	0.0018	0.0018	8	9	-0.64	-0.64
CVD2_Q9NQ25	SLAM family member 7	SLAMF7	0.0021	0.0026	9	11	0.71	0.64
100001577	N-acetylcitrulline	Urea cycle; Arginine and Proline Metabolism	0.0027	0.0091	10	27	-2.22	-1.65
NEX_O14944	epiregulin	EREG	0.0034	0.0115	11	36	2.57	2.09
100001162	propionylcarnitine	Fatty Acid Metabolism (& BCAA Metabolism)	0.0035	0.0044	12	15	-0.89	-0.78
CVD2_O14763	TNF receptor superfamily, member 10b	TNFRSF10B	0.0038	0.0038	13	12	0.59	0.59
100008984	1-palmitoyl-2-palmitoleoyl-GPC (16:0/16:1)	Phospholipid Metabolism	0.0039	0.0116	14	38	-0.91	-0.60
CVD2_Q99523	sortilin 1	SORT1	0.0043	0.0043	15	14	0.68	0.68
100002784	2-oxoarginine		0.0054	0.0054	16	17	-1.77	-1.77
100000015	xanthurenate	Tryptophan Metabolism	0.0056	0.0056	17	18	-1.26	-1.26
1539	1-palmitoyl-2-oleoyl-GPC (16:0/18:1)	Phospholipid Metabolism	0.0057	0.0057	18	19	-0.30	-0.30
CVD2_P01241	growth hormone 1	GH1	0.0059	0.0051	19	16	3.66	3.40
999947671	X - 18921		0.0065	0.0065	20	21	1.17	1.17
100000276	maltotriose	Glycogen Metabolism	0.0068	0.0230	21	54	8.84	6.72
100000406	ribitol	Pentose Metabolism	0.0078	0.0154	22	42	-0.63	-0.38
INF_O43557	TNF (ligand) superfamily, member 14	TNFSF14	0.0080	0.0248	23	59	1.91	1.27
NEX_Q9Y680	FK506 binding protein 7	FKBP7	0.0082	0.0082	24	23	1.18	1.18
100009066	1-palmitoyl-2-oleoyl-GPI (16:0/18:1)	Phospholipid Metabolism	0.0082	0.0005	25	2	-1.41	-1.51
391	citrulline	Urea cycle; Arginine and Proline Metabolism	0.0084	0.0084	26	24	-0.51	-0.51
1002	allantoin	Purine Metabolism, Xanthine/Inosine	0.0084	0.0060	27	20	-0.47	-0.43
407	lysine	Lysine Metabolism	0.0088	0.0088	28	25	-0.21	-0.21
100001272	1-oleoyl-GPC (18:1)	Lysolipid	0.0090	0.0090	29	26	-0.43	-0.43
999933132	X - 11787		0.0094	0.0094	30	29	-0.31	-0.31
CVD2_P22004	bone morphogenetic protein 6	BMP6	0.0097	0.0309	31	78	1.04	0.81
533	urea	Urea cycle; Arginine and Proline Metabolism	0.0099	0.0099	32	31	-0.72	-0.72
999947802	X - 16397		0.0101	0.0101	33	33	0.83	0.83
100008904	1-stearoyl-2-oleoyl-GPC (18:0/18:1)	Phospholipid Metabolism	0.0108	0.0108	34	35	-0.49	-0.49
100000263	imidazole lactate	Histidine Metabolism	0.0108	0.0353	35	88	-0.35	-0.26
CVD2_Q14116	interleukin 18	IL18	0.0109	0.0370	36	92	0.86	0.60

Table 2. List of analytes most significantly altered by the COCOA intervention. These analytes have the most significant differences in analyte change between the two arms of the trial. They are not necessarily associated with outcomes. Analyte changes are computed as the difference in value between the first two timepoints, approximately four months apart — but with a few outliers due to the COVID pandemic (**Supplemental Figure 3**). The primary "full" analysis included all data points. A secondary "robust" analysis excluded outlier analyte values. For a comprehensive overview, consult **Supplemental Table 1**, and sort by the column(s) of interest.

Analyte ID	Name	Symbol or Pathway or System or Category	p-value (full)	p-value (robust)	Rank (full)	Rank (robust)	Effect Size (full)	Effect Size (robust)
999949679	X - 23780		4.8E-04	4.8E-05	1	3	0.0095	0.0129
501	salicylate	Drug	4.9E-04	6.1E-07	2	1	0.0005	0.0015
1869	2-hydroxyhippurate (salicylurate)	Benzoate Metabolism	5.5E-04	3.7E-04	3	5	0.0008	0.0014
999946515	X - 21470		0.0011	0.7889	4	1088	0.0217	-0.0018
100006108	phenylacetylcarnitine	Phenylalanine and Tyrosine Metabolism	0.0013	0.4061	5	496	-0.0111	-0.0025
100001294	gamma-glutamylglycine	Gamma-glutamyl Amino Acid	0.0027	0.0027	6	8	0.0321	0.0321
100000447	gentisate	Phenylalanine and Tyrosine Metabolism	0.0041	0.0001	7	4	0.0026	0.0089
100001870	1-palmitoyl-2-linoleoyl-GPE (16:0/18:2)	Phospholipid Metabolism	0.0055	0.0055	8	11	0.0282	0.0282
CVD3_Q86VB7	CD163 molecule	CD163	0.0061	0.0008	9	6	0.0339	0.0511
999949521	X - 23644		0.0069	0.0114	10	19	-0.0085	-0.0097
100000467	3-indoxyl sulfate	Tryptophan Metabolism	0.0090	0.0370	11	44	-0.0186	-0.0170
100001162	propionylcarnitine	Fatty Acid & BCAA Metabolism	0.0108	0.6409	12	851	-0.0231	-0.0034
NEU1_P09919	colony stimulating factor 3 (granulocyte)	CSF3	0.0108	0.0108	13	16	0.0246	0.0246
BASOPHILS	BASOPHILS ABSOLUTE		0.0112	0.0112	14	18	0.1689	0.1689
NEX_Q86Z14	klotho beta	KLB	0.0139	0.0220	15	27	0.0265	0.0309
100021666	isomers of 10:1 fatty acid		0.0143	0.0062	16	12	0.0154	0.0209
999946486	X - 21441		0.0145	0.0145	17	21	0.0165	0.0165
CVD2_Q8TAD2	interleukin 17D	IL17D	0.0173	0.0173	18	22	0.0398	0.0398
100021162	palmitoyl-sphingosine-phosphoethanolamine (d18:1/16:0)	Ceramide PEs	0.0178	0.0178	19	23	0.0440	0.0440
CVD3_Q9H2A7	chemokine (C-X-C motif) ligand 16	CXCL16	0.0192	0.0192	20	24	0.0433	0.0433
CVD3_P30530	AXL receptor tyrosine kinase	AXL	0.0198	0.0198	21	26	0.0410	0.0410
999949517	X - 23641		0.0220	0.0011	22	7	-0.0116	-0.0200
100020550	deoxycholic acid glucuronide	Secondary Bile Acid Metabolism	0.0237	0.1003	23	124	-0.0118	-0.0100
98	kynurenate	Tryptophan Metabolism	0.0249	0.0249	24	30	-0.0264	-0.0264
CVD3_O00300	TNF receptor superfamily, member 11b	TNFRSF11B	0.0254	0.0254	25	31	0.0303	0.0303
100006260	6-hydroxyindole sulfate	Chemical	0.0267	0.1086	26	132	-0.0157	-0.0134
1140	gamma-glutamylglutamine	Gamma-glutamyl Amino Acid	0.0286	0.0244	27	29	0.0239	0.0281
100019975	hexadecenedioate (C16:1-DC)	Fatty Acid, Dicarboxylate	0.0298	0.0598	28	74	0.0156	0.0157
	sort order switched from "full" to "robust" below this row							
100005367	N-acetylalliin	Food Component/Plant	0.4648	2.0E-05	541	2	-0.0006	-0.0075
100004295	2-piperidinone	Food Component/Plant	0.1397	0.0036	164	9	-0.0064	-0.0159
100004509	S-allylcysteine	Food Component/Plant	0.1483	0.0038	178	10	-0.0029	-0.0078
100009346	phosphatidylcholine (14:0/14:0, 16:0/12:0)	Phospholipid Metabolism	0.0323	0.0074	31	13	0.0087	0.0142
338	gluconate	Food Component/Plant	0.0828	0.0085	90	14	-0.0193	-0.0404
INF_P01579	interferon, gamma	IFNG	0.0536	0.0088	52	15	0.0043	0.0091
100021712	deoxycholic acid 12-sulfate	Secondary Bile Acid Metabolism	0.8453	0.0112	1169	17	-0.0004	-0.0111
CVD3_P05164	myeloperoxidase	MPO	0.0313	0.0122	30	20	0.0163	0.0252
CVD2_P00797	renin	REN	0.0937	0.0194	103	25	-0.0112	-0.0187
100001092	trigonelline (N'-methylnicotinate)	Nicotinate and Nicotinamide Metabolism	0.1357	0.0224	159	28	0.0038	0.0064
100009215	1-stearoyl-2-dihomo-linolenoyl-GPE (18:0/20:3n3 or 6)	Phospholipid Metabolism	0.1239	0.0270	141	32	0.0151	0.0261

Table 3. List of analytes most significantly correlated with MPI slope. Top analytes in this table may or may not necessarily be affected by the COCOA intervention. Variations in these analytes may be influenced by many factors driving differences between participants in both arms, including genetics and lifestyle choices not impacted by coaching. Analyte changes are computed as the difference in value between the first two timepoints, approximately four months apart — but with a few outliers due to the COVID pandemic (**Supplemental Figure 3**). The primary "full" analysis included all data points. A secondary "robust" analysis excluded outlier analyte values. For a comprehensive overview, consult **Supplemental Table 1**, and sort by the column(s) of interest.

Name	Intervention p-value (full)	Intervention p-value (robust)	MPI p-value (full)	MPI p-value (robust)	Intervention Rank (full)	Intervention Rank (robust)	MPI Rank (full)	MPI Rank (robust)	Intervention Effect (full)	Intervention Effect (robust)	MPI Effect (full)	MPI Effect (robust)
propionylcarnitine	0.004	0.004	0.011	0.641	12	15	12	851	-0.891	-0.784	-0.023	-0.003
kynurenate	0.002	0.002	0.025	0.025	8	9	24	30	-0.644	-0.644	-0.026	-0.026
gamma-glutamyl-alpha-lysine	0.016	0.010	0.033	0.152	54	32	33	194	-0.449	-0.392	0.025	0.022
albumin	0.039	0.039	0.034	0.034	126	103	36	39	-0.407	-0.407	-0.035	-0.035
gamma-glutamylmethionine	0.017	0.018	0.076	0.273	60	46	75	336	-0.938	-0.855	0.012	0.009
sphingomyelin (d18:1/20:1, d18:2/20:0)	0.014	0.014	0.089	0.089	47	40	96	111	0.273	0.273	0.048	0.048
hexadecanedioate (C16-DC)	0.043	0.043	0.098	0.098	136	111	110	122	1.050	1.050	0.011	0.011
interleukin 18 receptor 1	0.058	0.058	0.083	0.083	177	152	92	103	0.408	0.408	0.027	0.027
palmitoyl-sphingosine-phosphoethanolamine (d18:1/16:0)	0.061	0.061	0.018	0.018	182	156	19	23	0.323	0.323	0.044	0.044
N-acetyltryptophan	0.072	0.072	0.095	0.095	209	173	106	119	-0.557	-0.557	-0.016	-0.016
methionine	0.078	0.094	0.080	0.318	223	221	84	379	-0.156	-0.127	0.039	0.028
interleukin 17D	0.085	0.085	0.017	0.017	233	197	18	22	0.422	0.422	0.040	0.040
3,5-dichloro-2,6-dihydroxybenzoic acid	0.029	0.086	0.105	0.086	97	199	115	107	-0.435	-0.290	-0.022	-0.029
	sort order switched from "full" to "robust" below this row											
N-acetylkynurenine	0.038	0.048	0.391	0.052	122	127	445	63	-1.484	-1.342	-0.003	-0.008
interferon, gamma	0.952	0.099	0.054	0.009	1404	232	52	15	-0.172	1.631	0.004	0.009
tiglylcarnitine (C5:1-DC)	0.029	0.029	0.116	0.116	96	71	131	142	-0.434	-0.434	-0.018	-0.018
X - 16576	0.053	0.064	0.275	0.115	163	161	323	141	0.588	0.518	-0.009	-0.016
lysine	0.009	0.009	0.140	0.140	28	25	165	174	-0.211	-0.211	0.037	0.037
pregnenolone sulfate	0.117	0.075	0.759	0.135	303	179	1015	171	-5.470	-0.400	0.000	-0.018
phenyllactate (PLA)	0.117	0.025	0.299	0.144	302	60	348	180	-0.568	-0.626	-0.011	-0.018
N-stearoyl-sphingosine (d18:1/18:0)	0.203	0.047	0.209	0.154	444	120	243	195	0.545	0.661	0.014	0.019
N-palmitoyl-sphinganine (d18:0/16:0)	0.264	0.064	0.161	0.164	522	160	192	208	-0.329	-0.403	0.013	0.016
CSF 1 (macrophage)	0.090	0.090	0.157	0.157	248	212	187	200	0.264	0.264	0.025	0.025
N-acetylcitrulline	0.003	0.009	0.168	0.171	10	27	200	213	-2.225	-1.645	-0.005	-0.006
urea	0.031	0.031	0.179	0.179	102	77	208	219	-7.080	-7.080	-0.001	-0.001

Table 4. Candidate molecular mediators (rough ranking). Top analyte candidates for mediating the effect of the COCOA intervention on cognitive amelioration. Two sort orders for candidates are reflected in this table. The first list is derived from the primary "full" analysis including all data points. The second list is derived from a secondary "robust" analysis excluding outlier analyte values. The full analysis detects mediators that may be present in a minority of individuals but could play a big role in those individuals. Analytes with nominally significant effects for both the COCOA intervention and MPI correlation are listed first; following are those with at least a trend in both analyses, followed by the remaining analytes sorted by significance. The rough rankings in this table do not consider direction of effect or baseline differences between arms, which are both considered in the rankings in **Table 5**. For a comprehensive overview, consult **Supplemental Table 1**, and sort by the column(s) of interest.

Name	Intervention p-value (full)	Intervention p-value (robust)	MPI p-value (full)	MPI p-value (robust)	Intervention Rank (full)	Intervention Rank (robust)	MPI Rank (full)	MPI Rank (robust)	Intervention Effect (full)	Intervention Effect (robust)	MPI Effect (full)	MPI Effect (robust)
kynurenate	0.0018	0.0018	0.0249	0.0249	8	9	24	30	-0.644	-0.644	-0.026	-0.026
albumin	0.0395	0.0395	0.0339	0.0339	126	103	36	39	-0.407	-0.407	-0.035	-0.035
sphingomyelin (d18:1/20:1, d18:2/20:0)	0.0140	0.0140	0.0886	0.0886	47	40	96	111	0.273	0.273	0.048	0.048
hexadecanedioate (C16-DC)	0.0429	0.0429	0.0983	0.0983	136	111	110	122	1.050	1.050	0.011	0.011
N-acetylkynurenine	0.0384	0.0485	0.3906	0.0523	122	127	445	63	-1.484	-1.342	-0.003	-0.008
tiglylcarnitine (C5:1-DC)	0.0287	0.0287	0.1158	0.1158	96	71	131	142	-0.434	-0.434	-0.018	-0.018
interleukin 18 receptor 1	0.0578	0.0578	0.0832	0.0832	177	152	92	103	0.408	0.408	0.027	0.027
palmitoyl-sphingosine-phosphoethanolamine (d18:1/16:0)	0.0611	0.0611	0.0178	0.0178	182	156	19	23	0.323	0.323	0.044	0.044
N-acetyltryptophan	0.0716	0.0716	0.0953	0.0953	209	173	106	119	-0.557	-0.557	-0.016	-0.016
phenyllactate (PLA)	0.1167	0.0248	0.2990	0.1441	302	60	348	180	-0.568	-0.626	-0.011	-0.018
gamma-glutamyl-alpha-lysine	0.0157	0.0101	0.0331	0.1520	54	32	33	194	-0.449	-0.392	0.025	0.022
N-stearoyl-sphingosine (d18:1/18:0)	0.2026	0.0467	0.2086	0.1544	444	120	243	195	0.545	0.661	0.014	0.019
interleukin 17D	0.0851	0.0851	0.0173	0.0173	233	197	18	22	0.422	0.422	0.040	0.040
3,5-dichloro-2,6-dihydroxybenzoic acid	0.0294	0.0862	0.1050	0.0861	97	199	115	107	-0.435	-0.290	-0.022	-0.029
colony stimulating factor 1 (macrophage)	0.0902	0.0902	0.1572	0.1572	248	212	187	200	0.264	0.264	0.025	0.025
N-acetylcitrulline	0.0027	0.0091	0.1679	0.1714	10	27	200	213	-2.225	-1.645	-0.005	-0.006
urea (lab)	0.0306	0.0306	0.1787	0.1787	102	77	208	219	-7.080	-7.080	-0.001	-0.001
carotene diol	0.0942	0.0942	0.1633	0.1633	256	222	193	206	0.369	0.369	0.017	0.017
X - 15486	0.0420	0.0613	0.2577	0.1819	135	157	302	223	1.452	1.208	0.005	0.007
argininate	0.0658	0.0628	0.3190	0.1825	187	159	372	224	-0.826	-0.709	-0.006	-0.012
galactonate	0.0011	0.0007	0.8283	0.2020	6	4	1141	239	-6.762	-6.386	0.000	-0.002
2-hydroxyhippurate	0.6563	0.1088	0.0006	0.0004	1041	249	3	5	7.541	11.104	0.001	0.001
X - 15503	0.1117	0.1117	0.2126	0.2126	287	256	247	254	-0.314	-0.314	-0.013	-0.013
xanthurenate	0.0056	0.0056	0.2165	0.2165	17	18	253	260	-1.263	-1.263	-0.008	-0.008

Table 5. Candidate molecular mediators for multimodal interventions for individuals in the early stages of the AD spectrum. Candidates from **Table 4** were pruned to produce this list of "best candidates". First, candidates from the "full" and "robust" lists were combined. Then, two filters were employed: (1) analytes with an effect direction on MPI opposite to the COCOA intervention effect direction were excluded; (2) analytes with a higher likelihood of inflated significance for the effect of the intervention due to regression towards the mean were excluded (i.e., those with p-values < 0.05 for a difference between arms at baseline).



Supplemental Figure 1. CONSORT Flow Diagram for the COCOA Trial. Although there was some attrition during the trial, most participants stayed active long enough to contribute molecular data to at least two timepoints.



Supplemental Figure 2. Participation intervals for each participant. Attrition rates were comparable between the intervention (coaching) and control (standard of care) arms. 24-month completion rates rose slightly for individuals recruited later into the trial, possibly due to subtle effects of increased trial staff experience facilitating logistics and participant experience in the trial. The first vertical dotted line indicates the cessation of Arivale operations, and consequently the cessation of recruitment. The second vertical dotted line indicates the onset of the COVID pandemic. Neither of these events significantly increased the attrition (dropout) rate.



Supplemental Figure 3. Data collection timing for blood draws. Each participant had blood draws at up to 6 timepoints. Blood draws paused temporarily after Arivale ceased operations, as logistics were assumed in house. Blood draws also became infrequent during peak COVID pandemic waves. Some blood draws were skipped during these periods. Metabolomics, proteomics, and clinical labs were assayed from these blood draws. The original trial protocol aimed to collect blood at six timepoints: 0, 4, 8, 12, 18, and 24 months.



Supplemental Figure 4. Linearized MPI trajectories of COCOA Participants. The coaching arm has less decline in cognition than the standard-of-care arm. Although a linear fit does not fully capture the dynamics of the trajectories, this standard approach had been selected to be the primary test of the primary outcome measure. Some final MPI assessments were delayed past 24 months due to the COVID pandemic. Trajectories are computed with linear regression. Change from baseline is graphed. 90% confidence intervals are shaded.



Supplemental Figure 5. Individual MPI trajectories of COCOA Participants. Individual trajectories are highly variable. Although the COCOA intervention shows a benefit in aggregate in this population, any particular individual may not have an overall benefit, and any benefit may wax and wane.



Supplemental Figure 6. Linearized MoCA trajectories of COCOA Participants. The coaching arm has less decline in cognition than the standard-of-care arm. Trajectories are computed with linear regression. 90% confidence intervals are shaded.



Supplemental Figure 7. Linearized FAST trajectories of COCOA Participants. The coaching arm has less decline in function than the standard-of-care arm. Trajectories are computed with linear regression. 90% confidence intervals are shaded.



Supplemental Figure 8. Individual FAST trajectories of COCOA Participants. There are a greater number of intervals showing improvement (decrease of a point) in the coaching arm than in the standard-of-care arm. The COCOA intervention may occasionally reverse the process of disease in some individuals. Points are jittered to avoid overprinting.



Supplemental Figure 9. MoCA trajectory in ADNI. The ADNI MoCA trajectory can be compared to the MPI trajectory of the COCOA control arm, using a conversion factor. The ADNI MoCA trajectory is linear for the first two years, but becomes somewhat nonlinear beyond that (not shown). 90% confidence interval shaded.



Supplemental Figure 10. Relationship of kynurenate change to MPI change in COCOA. A single individual with one of the largest drops in kynurenate shows the largest increase in cognition. The remaining individuals show a smaller (and much less significant) anticorrelation suggesting that kynurenate may play a large role in a single individual, and a small role in many individuals (sex-adjusted pvalue with outlier = 0.025; without outlier = 0.17), highlighting the multimodal nature of Alzheimer's disease (AD) portrayed in **Figure 1**. It is possible that better targeting of kynurenate-implicated pathways with an improved intervention could better leverage this mediator in a larger number of affected individuals.